{
    "nctId": "NCT05878314",
    "briefTitle": "Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer",
    "officialTitle": "Impact of Preoperative Endocrine Therapy, Menstrual Cycle, PAM50 Assessment and Ki67 Dynamics on Adjuvant Treatment Decisions in Hormone Receptor-positive and HER2-negative Patients With Early Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Hormone Receptor Positive HER-2 Negative Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 504,
    "primaryOutcomeMeasure": "Influence of the menstrual cycle on initial Ki67 in premenopausal women",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* women \u2265 18 years of age\n* histologically proven unilateral primary non-metastatic invasive breast cancer\n* Estrogen receptor (ER)-/ or Progesterone receptor (PR)- positive and HER2-negative\n* Ki67 from core biopsy is available\n* no lymph-node involvement by clinical evaluation and ultrasound (cN0)\n* not amendable to neoadjuvant chemotherapy\n* surgery or planned surgery at the Department for Women's Health, Tuebingen or Freiburg\n* planned preoperative endocrine treatment with Tamoxifen, Aromatase inhibitors, Goserelin or nothing for 2 - 4 weeks\n* written informed consent\n\nExclusion Criteria:\n\n* ER-negative and PR-negative\n* HER2-positive\n* bilateral breast cancer\n* preexisting cancer disease within the last 10 years\n* preexisting invasive ipsi- or contralateral breast cancer (non-invasive ipsi- or contralateral breast cancer is not regarded as an exclusion criteria)\n* any systemic breast cancer therapy before inclusion into the trial\n* indication for neoadjuvant chemotherapy\n* any systemic therapy except Tamoxifen, Aromatase inhibitors, Goserelin before surgery\n* locally advanced, inoperable or metastatic breast cancer\n* pregnant or lactating patients\n* inadequate general condition (not fit for chemotherapy)\n* hormonal contraception within 6 months before inclusion",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}